Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Immtech Wins Fast-Track for Pafuramidine from SFDA

publication date: Sep 27, 2007

Immtech Pharmaceuticals was granted Fast Track Status from the State FDA of China for pafuramidine, an oral drug undergoing testing as a treatment for Pneumocystis pneumonia (PCP). Pafuramidine is one of the first drugs to win Fast Track Status under new, more stringent rules recently established by the SFDA. The compound was previously given both Fast Track and Orphan Drug status in the US. More details...

Stock Symbol: (AMEX: IMM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital